Get started
Author

Wanying Zhao

Observed name: Wanying Zhao, PhD
Observed institution: Curis (United States)
OpenAlex ID: A5070936646
Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation
2023 · Eric S. Winer, Amit Verma, et al. · Blood · 6
Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients with Prior Exposure to BTK Inhibitor
2024 · Grzegorz S. Nowakowski, Anna Paulina Dabrowska-Iwanicka, et al. · Blood · 5
PDF
Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
2023 · Christian Grommes, Han Tun, et al. · Blood · 5
PDF
Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)
2024 · Guillermo Garcia-Manero, David Sallman, et al. · Blood · 4
PDF
Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
2024 · Eric S. Winer, David Sallman, et al. · Blood · 3
PDF
Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).
2024 · Christian Grommes, Han W. Tun, et al. · Journal of Clinical Oncology · 2
Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies.
2024 · Klaus H Metzeler, Uwe Platzbecker, et al. · Journal of Clinical Oncology · 2
Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
2022 · Klaus H. Metzeler, Eric S. Winer, et al. · Blood · 2
A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).
2024 · Adolfo de la Fuente Burguera, Claudio Cerchione, et al. · Journal of Clinical Oncology · 1
Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m).
2024 · Eric S. Winer, Amit Verma, et al. · Journal of Clinical Oncology · 1
Ctim-34. Preliminary Safety and Efficacy Data on Two Patients With Relapsed/refractory Cns Lymphoma Treated With Emavusertib (ca-4948) and Ibrutinib Combination: a Subset Analysis of Takeaim Lymphoma Trial
2022 · Madiha Iqbal, Han Tun, et al. · Neuro-Oncology · 1
PDF
Ctni-59. Analysis of Genetic Mutation Profile and Cns Pharmacokinetics in Relapsed/refractory Primary Cns Lymphoma Patients Responding to Novel Emavusertib (irak4i) and Btki Combination
2025 · Christian Grommes, MD, Anna Dabrowska-Iwanicka, MD, et al. · Neuro-Oncology
PDF
Ctni-63. Preliminary Safety and Efficacy of Emavusertib (ca-4948) in Combination With Ibrutinib in Relapsed/refractory Primary Central Nervous System Lymphoma Patients
2025 · Lakshmi Nayak, MD, Anna Dabrowska-Iwanicka, MD, et al. · Neuro-Oncology
PDF
Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination.
2025 · Christian Grommes, Anna P. Dabrowska-Iwanicka, et al. · Journal of Clinical Oncology
688 Transcriptome analyses in patients with myeloid malignances treated with the IRAK4 inhibitor emavusertib
2023 · Klaus H Metzeler, Uwe Platzbecker, et al. · Regular and Young Investigator Award Abstracts
PDF
Works count: 15
Citation count: 32
H-index: 4
I10-index:
Year
Topic
Type